- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06056362
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Evaluation of Biodistribution, Dosimetry, Diagnostic Ability, and Safety of Al18F-NOTA-LM3 in Patients With Well-differentiated Neuroendocrine Tumors, and Comparison With 68Ga-DOTATATE and 68Ga-NODAGA-LM3: A Prospective, Single-center, Double-blinded Study
Study Overview
Status
Conditions
Detailed Description
Somatostatin receptors (SSTR), especially SSTR subtype 2 (SSTR2), are highly expressed in well-differentiated neuroendocrine tumors (NETs). Radiolabeled somatostatin analogs, including 68Ga-DOTATATE, are widely used for NET imaging and play essential roles in primary tumor seeking, staging, as well as management. SSTR antagonists have recently emerged as another type of somatostatin analog and showed better performance than analogs. Our previous studies exhibited better diagnostic efficacy of 68Ga-DOTA-LM3, 68Ga-DOTA-JR11, and 68Ga-NODAGA-LM3 compared to 68Ga-DOTATATE, especially liver metastasis.
18F-labeled radiotracers have shown several advantages compared to 68Ga-labelled tracers, including increased cyclotron production, lower positron energy, and longer half-life when compared to 68Ga, theoretically to the benefit of image quality. The purpose of this study is to investigate the biodistribution, safety, and diagnostic ability of Al18F-NOTA-LM3 in patients with well-differentiated neuroendocrine tumors. And compare the diagnostic ability of Al18F-NOTA-LM3 with 68Ga-DOTATATE PET/CT and 68Ga-NODAGA-LM3 PET/CT. Clinical management related to imaging will also be compared.
Patients with histologically confirmed well-differentiated neuroendocrine tumors (G1 and G2) will be recruited in this study. All patients will be randomized into two arms (A and B): Patients in arm A performed Al18F-NOTA-LM3 and 68Ga-DOTATATE. Patients in arm B performed Al18F-NOTA-LM3 and 68Ga-NODAGA-LM3. The first eight patients will undergo serial PET scans at 5, 15, 30, 45, 60, and 120 min after injection of Al18F-NOTA-LM3. The following patients will perform a whole-body PET/CT scan at 60-90 minutes after injection of Al18F-NOTA-LM3. All patients a whole-body PET/CT scan at 40-60 minutes after administering 68Ga-DOTATATE or 68Ga-NODAGA-LM3. For each patient, the two pet scans should be done within a week and the interval between the two scans should be at least 24h in case of mutual interference.
The images were reviewed by 2 experienced nuclear medicine physicians who were masked to all patients' clinical information. The results were based on consensus, with any discrepant result resolved by a consensus image interpretation by a third senior physician.
The biodistribution, dosimetry, safety, and diagnostic ability of Al18F-NOTA-LM3 will be explored. The diagnostic ability of Al18F-NOTA-LM3 with 68Ga-DOTATATE PET/CT and 68Ga-NODAGA-LM3 PET/CT will be compared. We will also compare the clinical management using different imaging modalities.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Meixi Liu, MD
- Phone Number: +86-15010405355
- Email: meixiliu_pumc@126.com
Study Contact Backup
- Name: Li Huo, MD
- Phone Number: +86-13910801986
- Email: huoli@pumch.cn
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Shuyang Zhang, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 18 to 80 years.
- Histologically proven, well-differentiated, NETs (G1 or G2).
- No long-acting somatostatin analog treatment within 4 weeks.
- No PRRT treatment within 8 weeks.
Exclusion Criteria:
- Combined with other types of tumors.
- Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR<30ml/min).
- Active infection.
- Pregnant or breast-feeding women.
- Inability to perform PET/CT scans.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Al18F-NOTA-LM3 and 68Ga-DOTATATE group
Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-DOTATATE PET/CT.
|
40 patients will be enrolled in this arm.
The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3.
The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE.
68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
40 patients will be enrolled in this arm.
All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
|
Experimental: Arm B: Al18F-NOTA-LM3 and 68Ga-NODAGA-LM3 group
Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-NODAGA-LM3 PET/CT.
|
40 patients will be enrolled in this arm.
The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3.
The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
40 patients will be enrolled in this arm.
All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3.
68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Al18F-NOTA-LM3
Time Frame: From radiotracer injection to 24 hours post-injection.
|
Adverse effects were recorded according to CTCAE (version 5.0) after radiotracer injection and PET scan.
|
From radiotracer injection to 24 hours post-injection.
|
Detection rate of Al18F-NOTA-LM3 on per-patient basis
Time Frame: From study completion to 6 months after completion.
|
Percentage of patients with lesions detected on Al18F-NOTA-LM3 PET/CT.
|
From study completion to 6 months after completion.
|
SUVmax of lesions detected on Al18F-NOTA-LM3 PET/CT
Time Frame: From study completion to 6 months after completion.
|
The tracer uptake is quantified using maximal standard uptake value (SUVmax) by drawing a 3-dimensional region of interest.
|
From study completion to 6 months after completion.
|
Detection rate of 68Ga-DOTATATE on per-patient basis
Time Frame: From study completion to 6 months after completion.
|
Percentage of patients with lesions detected on 68Ga-DOTATATE PET/CT.
|
From study completion to 6 months after completion.
|
SUVmax of lesions detected on 68Ga-DOTATATE PET/CT
Time Frame: From study completion to 6 months after completion.
|
The tracer uptake is quantified using maximal standard uptake value (SUVmax) by drawing a 3-dimensional region of interest.
|
From study completion to 6 months after completion.
|
Detection rate of 68Ga-NODAGA-LM3 on per-patient basis
Time Frame: From study completion to 6 months after completion.
|
Percentage of patients with lesions detected on 68Ga-NODAGA-LM3 PET/CT.
|
From study completion to 6 months after completion.
|
SUVmax of lesions detected on 68Ga-NODAGA-LM3 PET/CT
Time Frame: From study completion to 6 months after completion.
|
The tracer uptake is quantified using maximal standard uptake value (SUVmax) by drawing a 3-dimensional region of interest.
|
From study completion to 6 months after completion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SUVmax of normal organs
Time Frame: From study completion to 6 months after completion.
|
The biodistribution of Al18F-NOTA-LM3 will be evaluated in the following organs: pituitary gland, parotids, thyroids, lungs, blood pool, liver, spleen, pancreas (head and uncinate process), gallbladder, stomach, small intestine, kidneys, and adrenal glands.
SUVmax of these organs were measured and recorded.
|
From study completion to 6 months after completion.
|
Absorbed dose of target organs
Time Frame: From study completion to 6 months after completion.
|
Absorbed dose of target organs were calculated using HERMES software.
|
From study completion to 6 months after completion.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Meixi Liu, MD, Peking Uion Medical College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALFLM3NET
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Francesco De CobelliCompleted
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
Clinical Trials on Al18F-NOTA-LM3
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Peking Union Medical College HospitalActive, not recruiting
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Xiangya Hospital of Central South UniversityUnknownNeuroendocrine NeoplasmChina
-
Universitaire Ziekenhuizen KU LeuvenCompletedNeuroendocrine TumorsBelgium
-
Peking Union Medical College HospitalUnknown
-
Universitaire Ziekenhuizen KU LeuvenUniversity Hospital, Ghent; University Hospital, Antwerp; NETwerk, BelgiumCompleted
-
Peking Union Medical College HospitalCompleted
-
Xiangya Hospital of Central South UniversityUnknown
-
The First Affiliated Hospital of Soochow UniversityNot yet recruiting